Country for PR: United States
Contributor: PR Newswire New York
Thursday, August 13 2020 - 23:00
AGC Biologics Enters into Partnership as a CDMO with Ono Pharmaceuticals to Manufacture Biopharmaceuticals at Clinical Development Stage
SEATTLE, Aug. 13, 2020 /PRNewswire-AsiaNet/ --

AGC Biologics, a global biopharmaceutical Contract Development and 
Manufacturing Organization (CDMO), announced it is partnering with Ono 
Pharmaceutical Co., Ltd. (ONO) to manufacture new, innovative 
biopharmaceuticals at the clinical development stage. ONO is a R&D-oriented 
pharmaceutical company committed to discovering and developing innovative drugs.

Logo - 

"We are very pleased to initiate this partnership with ONO," said Mark Womack, 
CBO of AGC Biologics. "We look forward to closely collaborating with ONO to 
manufacture innovative and important therapies."

AGC Biologics' global network spans three continents, with cGMP-compliant 
facilities in Seattle, Washington; Boulder, Colorado; Copenhagen, Denmark; 
Heidelberg, Germany; Milan and Bresso, Italy and Chiba, Japan. Their best in 
class services include development and manufacturing of mammalian and 
microbial-based therapeutic proteins, plasmid DNA (pDNA), viral vectors and 
genetically engineered cells.

About ONO:  
ONO, headquartered in Osaka, is committed to creating innovative medicines in 
specific areas. ONO focuses its research on the oncology, immunology, neurology 
and specialty research with high medical needs as priority areas for discovery 
and development of innovative medicines. For further information, please visit 
the company's website at

About AGC Biologics:  
AGC Biologics is a leading global Biopharmaceutical Contract Development and 
Manufacturing Organization (CDMO) with a strong commitment to deliver the 
highest standard of service to clients and partners. The company currently 
employs more than 1,300 employees worldwide.  AGC Biologics has decades of 
experience in CDMO development and manufacturing, including providing 
commercial market supply with FDA, PDMA and EMA approvals.

AGC Biologics offers deep industry expertise and unique customized services. 
Integrated service offerings include cell line development, bioprocess 
development, formulation, analytical testing, antibody drug development and 
conjugation, cell banking and storage and protein expression, including the 
proprietary CHEF1(R) Expression System for mammalian production.

AGC Biologics is committed to continuous innovation and offers the technical 
creativity to solve clients' most complex challenges, including specialization 
in fast-track projects for orphan drugs and rare diseases.

Learn more at 

SOURCE: AGC Biologics 

CONTACT: Diane Hunt,,